This page shows the latest Brintellix news and features for those working in and with pharma, biotech and healthcare.
NICE has recommended Lundbeck's Brintellix for adults with major depressive order in final draft guidance. ... The submission included data from the REVIVE trial which compared Brintellix with Servier's Valdoxan (agomelatine).
Lundbeck's focus will now turn more to its newer drugs such as Brintellix (vortioxetine), Northera (droxidopa), Onfi (clobazam) and Abilify Maintena (aripriprazole) which saw a 190% growth in sales.
US filing aims to elevate Brintellix above its competition. Drug looking for an edge in the highly competitive major depressive disorder market. ... Lundbeck and Takeda have filed for US approval of new labelling for their antidepressant Brintellix that
Meanwhile, Rexulti is one of string of new drugs at Lundbeck - along with the likes of long-acting aripiprazole depot Abilify Maintena (also partnered with Otsuka) and new antidepressant Brintellix (vortioxetine) -
120m kroner and antidepressant Brintellix (vortioxetine) adding another 98m kroner, up from 8m kroner a year ago. ... Brintellix has now been launched in 20 countries and while uptake is "still limited outside the Nordic countries and the Netherlands,"
Brintellix first antidepressant with cognition claim in Europe. Trial found it performed better than Lilly’ s rival Cymbalta. ... The Danish company also has a long-acting version of schizophrenia drug Abilify (aripiprazole) and alcohol addiction
More from news
Approximately 8 fully matching, plus 19 partially matching documents found.
In addition, Lundbeck also has Brintellix (vortioxetine) under review by the EMA, while a once-monthly version of schizophrenia drug Abilify (aripiprazole) is also due to launch during 2013.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.